Published online before print April 14, 2003, doi: 10.1161/01.CIR.0000065579.19126.B8
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:2499.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
Postinfarction Treatment With an Adenoviral Vector Expressing Hepatocyte Growth Factor Relieves Chronic Left Ventricular Remodeling and Dysfunction in Mice
From the Second Department of Internal Medicine (Y.L., G.T., M.E., K.H., M.K., Y.K., R.M., H.O., S.M., H.F.) and Department of Gene Therapy and Regenerative Medicine (K.K., K.Y., S.N., M.E., K.G., T.T., H.F.), Gifu University School of Medicine, Gifu; the Division of Biological Chemistry and Biologicals, National Institute of Health Science, Tokyo (H.M.); and the Department of Food Science, Kyoto Women’s University, Kyoto (T.F.), Japan.
Correspondence to Hisayoshi Fujiwara, MD, PhD, Second Department of Internal Medicine, Gifu University School of Medicine, 40 Tsukasa-Machi, Gifu 500-8705, Japan. E-mail gifuim-gif{at}umin.ac.jp
Background— Hepatocyte growth factor (HGF) is implicated in tissue regeneration, angiogenesis, and antiapoptosis. However, its chronic effects are undetermined on postinfarction left ventricular (LV) remodeling and heart failure.
Methods and Results— In mice, on day 3 after myocardial infarction (MI), adenovirus encoding human HGF (Ad.CAG-HGF) was injected into the hindlimb muscles (n=13). As a control (n=15), LacZ gene was used. A persistent increase in plasma human HGF was confirmed in the treated mice: 1.0±0.2 ng/mL 4 weeks later. At 4 weeks after MI, the HGF-treated mice showed improved LV remodeling and dysfunction compared with controls, as indicated by the smaller LV cavity and heart/body weight ratio, greater % fractional shortening and LV ±dP/dt, and lower LV end-diastolic pressure. The cardiomyocytes near MI, including the papillary muscles and trabeculae, were greatly hypertrophied in the treated mice. The old infarct size was similar between the groups, but the infarct wall was thicker in the treated mice, where the density of noncardiomyocyte cells, including vessels, was greater. Fibrosis of the ventricular wall was significantly reduced in them. Examination of 10-day-old MI revealed no proliferation or apoptosis but showed augmented expression of c-Met/HGF receptor in cardiomyocytes near MI, whereas a greater proliferating activity and smaller apoptotic rate of granulation tissue cells in the HGF-treated hearts was observed compared with controls.
Conclusions— Postinfarction HGF gene therapy improved LV remodeling and dysfunction through hypertrophy of cardiomyocytes, infarct wall thickening, preservation of vessels, and antifibrosis. These findings imply a novel therapeutic approach against postinfarction heart failure.
Key Words: congestive heart failure • gene therapy • hepatocyte growth factor • myocardial infarction
This article has been cited by other articles:
 |
|
 |
|
  N. Sekiya, G. Matsumiya, S. Miyagawa, A. Saito, T. Shimizu, T. Okano, N. Kawaguchi, N. Matsuura, and Y. Sawa Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart. J. Thorac. Cardiovasc. Surg., October 1, 2009; 138(4): 985 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mizukami, K. Ono, C.-K. Du, T. Aki, N. Hatano, Y. Okamoto, Y. Ikeda, H. Ito, K. Hamano, and S. Morimoto Identification and physiological activity of survival factor released from cardiomyocytes during ischaemia and reperfusion Cardiovasc Res, September 1, 2008; 79(4): 589 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Carlsson, N. F. Osman, P. C. Ursell, A. J. Martin, and M. Saeed Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H522 - H532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fukui, S. Kitagawa-Sakakida, S. Kawamata, G. Matsumiya, N. Kawaguchi, N. Matsuura, and Y. Sawa Therapeutic Effect of Midkine on Cardiac Remodeling in Infarcted Rat Hearts Ann. Thorac. Surg., February 1, 2008; 85(2): 562 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Esaki, G. Takemura, K.-i. Kosai, T. Takahashi, S. Miyata, L. Li, K. Goto, R. Maruyama, H. Okada, H. Kanamori, et al. Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1048 - H1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ventura, S. Cantoni, F. Bianchi, V. Lionetti, C. Cavallini, I. Scarlata, L. Foroni, M. Maioli, L. Bonsi, F. Alviano, et al. Hyaluronan Mixed Esters of Butyric and Retinoic Acid Drive Cardiac and Endothelial Fate in Term Placenta Human Mesenchymal Stem Cells and Enhance Cardiac Repair in Infarcted Rat Hearts J. Biol. Chem., May 11, 2007; 282(19): 14243 - 14252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsuoka, T. H. Sisson, T. Nishiuma, and R. H. Simon Plasminogen-Mediated Activation and Release of Hepatocyte Growth Factor from Extracellular Matrix Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 705 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Tenhunen, Y. Soini, M. Ilves, J. Rysa, J. Tuukkanen, R. Serpi, H. Pennanen, H. Ruskoaho, and H. Leskinen p38 Kinase rescues failing myocardium after myocardial infarction: evidence for angiogenic and anti-apoptotic mechanisms FASEB J, September 1, 2006; 20(11): 1907 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, G. Takemura, H. Okada, S. Miyata, R. Maruyama, L. Li, M. Higuchi, S. Minatoguchi, T. Fujiwara, and H. Fujiwara Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure Cardiovasc Res, September 1, 2006; 71(4): 684 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, G. Takemura, Y. Li, S. Miyata, M. Esaki, H. Okada, H. Kanamori, N. C. Khai, R. Maruyama, A. Ogino, et al. Preventive Effect of Erythropoietin on Cardiac Dysfunction in Doxorubicin-Induced Cardiomyopathy Circulation, January 31, 2006; 113(4): 535 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nagaya, K. Kangawa, T. Itoh, T. Iwase, S. Murakami, Y. Miyahara, T. Fujii, M. Uematsu, H. Ohgushi, M. Yamagishi, et al. Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy Circulation, August 23, 2005; 112(8): 1128 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okada, G. Takemura, K.-i. Kosai, Y. Li, T. Takahashi, M. Esaki, K. Yuge, S. Miyata, R. Maruyama, A. Mikami, et al. Postinfarction Gene Therapy Against Transforming Growth Factor-{beta} Signal Modulates Infarct Tissue Dynamics and Attenuates Left Ventricular Remodeling and Heart Failure Circulation, May 17, 2005; 111(19): 2430 - 2437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Futamatsu, J.-i. Suzuki, S. Mizuno, N. Koga, S. Adachi, H. Kosuge, Y. Maejima, K. Hirao, T. Nakamura, and M. Isobe Hepatocyte Growth Factor Ameliorates the Progression of Experimental Autoimmune Myocarditis: A Potential Role for Induction of T Helper 2 Cytokines Circ. Res., April 29, 2005; 96(8): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, G. Takemura, K.-i. Kosai, T. Takahashi, H. Okada, S. Miyata, K. Yuge, S. Nagano, M. Esaki, N. C. Khai, et al. Critical Roles for the Fas/Fas Ligand System in Postinfarction Ventricular Remodeling and Heart Failure Circ. Res., September 17, 2004; 95(6): 627 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Komamura, R. Tatsumi, J.-i. Miyazaki, K. Matsumoto, E. Yamato, T. Nakamura, Y. Shimizu, T. Nakatani, S. Kitamura, H. Tomoike, et al. Treatment of Dilated Cardiomyopathy With Electroporation of Hepatocyte Growth Factor Gene Into Skeletal Muscle Hypertension, September 1, 2004; 44(3): 365 - 371. [Abstract] [Full Text] [PDF]
|
|